Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Heska Corp (NASDAQ:HSKA)

98.72
Delayed Data
As of Mar 24
 +0.49 / +0.50%
Today’s Change
26.26
Today|||52-Week Range
99.98
+37.88%
Year-to-Date
Merrimack (MACK) Starts Enrollment in Solid Tumors Study
Mar 24 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: American Woodmark, Heska, OraSure Technologies, Pionee...
Mar 20 / Zacks.com - Paid Partner Content
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA
Mar 24 / Zacks.com - Paid Partner Content
Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
Mar 17 / Zacks.com - Paid Partner Content
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
Mar 23 / Zacks.com - Paid Partner Content
Alkermes Starts Phase III Study to Treat Multiple Sclerosis
Mar 17 / Zacks.com - Paid Partner Content
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
Mar 23 / Zacks.com - Paid Partner Content
Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase
Mar 17 / Zacks.com - Paid Partner Content
Alexion (ALXN) Files for Soliris' Label Expansion in Japan
Mar 23 / Zacks.com - Paid Partner Content
Top 5 Efficient Stocks to Buy Right Now
Mar 17 / Zacks.com - Paid Partner Content
Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12%
Mar 23 / Zacks.com - Paid Partner Content
Shire's (SHPG) Cinryze Label Expanded for Pediatric Use
Mar 16 / Zacks.com - Paid Partner Content
XBiotech (XBIT) Catches Eye: Stock Moves Up 11.6% in Session
Mar 23 / Zacks.com - Paid Partner Content
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA
Mar 16 / Zacks.com - Paid Partner Content
Keryx's Auryxia Added to Largest Medicare Part D Plan
Mar 22 / Zacks.com - Paid Partner Content
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4
Mar 16 / Zacks.com - Paid Partner Content
Mylan Receives Tentative Approval from FDA for HIV Therapy
Mar 21 / Zacks.com - Paid Partner Content
Allergan (AGN) and Editas Tie Up to Treat Eye Diseases
Mar 15 / Zacks.com - Paid Partner Content
Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA
Mar 21 / Zacks.com - Paid Partner Content
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
Mar 15 / Zacks.com - Paid Partner Content
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
Mar 21 / Zacks.com - Paid Partner Content
Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4
Mar 14 / Zacks.com - Paid Partner Content
Alnylam's LDL-Lowering Drug Positive in Phase II Study
Mar 20 / Zacks.com - Paid Partner Content
Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8%
Mar 14 / Zacks.com - Paid Partner Content